BioStem is dedicated to the relentless pursuit of healing through our commitment to innovation and quality.
Since 2014, BioStem Technologies, Inc. has been a leading biomedical innovator, trusted by clinicians across specialties to deliver best-in-class healing solutions for advanced Surgical Care and advanced Wound Care. We’re passionate about boldly advancing innovation while upholding the principles of good stewardship that have led to us to where we are today, delivering high quality placental allograft products that inspire confidence in our clinicians and partners and help patients improve their lives.
MEET OUR LEADERSHIP AND BOARD OF DIRECTORS:
BOARD OF DIRECTORS
Jason Matuszewski
Chair of the Board
Kenneth Warrington, PhD
Audit Committee Member
Andrew Van Vurst, CTBS
Board Member
Jodi Ungrodt
Board Member
Rayna Lesser Hannaway
Board Member
Mark Glickman
Board Member
Steven D. Sonenreich
Board Member
Jason Matuszewski
Chair of the Board
Jason Matuszewski brings a wealth of experience in strategic operations planning and technical projects management from his rigorous technical background. His diverse expertise includes continuous process improvement, training and development programs, regulatory compliance and best practices implementation, and advanced problem solving. He began his career as a technical engineer working for Adecco at SC Johnson in 2009, where he developed comprehensive maintenance plans to support manufacturing processes at scale. He then transitioned to manufacturing and quality engineering for major organizations, including ATI Ladish Forging, Nemak, and HUSCO International, where he spearheaded process design and implementation, solved complex supply-chain and manufacturing problems, and improved product sourcing and purchasing. His philanthropic work with the Juvenile Diabetes Research Foundation sparked an interest in biotech, leading him to co-found BioStem Technologies in 2014. As CEO he has leveraged his expertise to optimize tissue sourcing, strategically build out a 6,000 square foot tissue processing facility that is fully compliant with FDA 210, 211, 1271, and AATB standards, and put together an expert team of professionals to support the company’s continued growth. Jason holds a B.S. in Mechanical Engineering Technology and a minor in Mathematics from the Milwaukee School of Engineering and is Six Sigma Black Belt certified. He also serves as a Processing and Distribution Council Member for the American Association of Tissue Banks (AATB), as well as serves as a member of the Government Affairs committee for BioFlorida. Jason was chosen as Ernst and Young’s Entrepreneur of The Year 2025 Florida award winner, by an independent panel of past winners, top CEOs, private equity and venture capital investors and business leaders. Judges assessed candidates on long-term value creation, entrepreneurial spirit, purpose-driven commitment and significant growth and impact.
Kenneth Warrington, PhD
Audit Committee Member
Kenneth Warrington, Ph.D., has decades of broad expertise across the cell and gene therapy product development continuum from discovery through GMP-compliant manufacturing to support IND-enabling pre-clinical and early-stage clinical programs. He has deep knowledge in advanced therapy manufacturing, including live attenuated and virus-like particle vaccines, live challenge viruses, viral vectors, and cell & gene-modified cell therapies. He served on the faculty at the University of Florida, Pediatrics-Division of Cellular & Molecular Therapy, with a research program focused on AAV vector development and production. Following his transition into industry in 2008, Dr. Warrington has held the lead technical operation and business development roles for global contract testing and manufacturing organizations, including Meridian Life Science, SGS Life Science, and Wuxi Apptec. He was formerly the SVP of Operations and Business Development at Biostem Life Sciences before assuming the role of chairman of the scientific advisory board. Dr. Warrington is currently Head of Strategy & Innovation and a Sr. Director of Business Development at GenScript ProBio, leading their gene & cell therapy CMC services, and Chief Technology Officer at Lacerta Therapeutics. He holds a B.S. in Biology & Chemistry from St. Lawrence University and a Ph.D. in Pharmacology & Experimental Therapeutics from the University of Florida.
Andrew Van Vurst, CTBS
Board Member
Andrew Van Vurst is an armed forces veteran and manufacturing operations expert with over eight years of experience working in FDA-regulated pharmaceutical and tissue processing firms. Before beginning his biopharmaceutical career, Andrew served as an aviation mechanic and flight captain in the United States Marine Corps. His military background instilled a high level of discipline, a strong commitment to compliance with industry protocol, and a paradigm for effective leadership that has served him well in subsequent roles. He co-founded Biostem Technologies in 2014 and played a pivotal role in the development of the company, working to establish revenue streams, ensure compliance with FDA and state pharmacy board guidelines, and adhere to FINRA and SEC guidelines for eventual public listing. During the early years with BioStem Technologies, he worked as Director of Operations for Nesvik Pharmaceuticals and Qualified Pharma Ingredients, where he managed research and development activities for four 505(b)(2) products and built out an API repackaging facility from the ground up until 2019. Throughout these roles, he brought several compounds from the idea phase to pre-IND submission and eventually sold the API repackaging business. Today as COO, he continues to oversee lab production and quality assurance operations, supporting Biostem’s excellence in tissue processing. Andrew studied at Florida Gulf Coast University and has completed Landmark Courses to hone advanced leadership skills. He serves as a Processing and Distribution Council Member for the American Association of Tissue Banks (AATB) and is an AATB-certified Tissue Banking Specialist.
Jodi Ungrodt
Board Member
Jodi Ungrodt has spent her career operating as a risk and accounting advisor and strategic partner for Life Science companies. As a senior partner at Ernst & Young LLP, a $50B organization operating in 150 countries, Jodi has deep experience in initial and secondary public offerings, business combinations, debt and equity transactions, risk assessment, regulatory compliance, and talent management. Her experience at EY and as a long-serving board member for Feeding San Diego includes providing diverse and forward-thinking perspectives, cognitive opposition, and active involvement and honest communication. As a recognized industry expert and thought leader, Jodi stays on the cutting edge of market, business, and global matters and their financial and business implications. She is well-respected and connected throughout the Life Sciences industry with business leaders, VCs, and the legal and business insurance community. Jodi’s depth and breadth of accounting and industry expertise, combined with her expansive network of connections, empower her to immediately contribute to board oversight roles and engage board colleagues and management with clear, strategic, and innovative insights. She is also qualified to serve as a financial expert under SEC, NYSE, and NASDAQ rules.
Rayna Lesser Hannaway
Board Member
Rayna Lesser Hannaway is a small-cap specialist who spent 29 years as an institutional investor, studying thousands of innovative companies across market cycles. She began her career in small-cap equity research at Lord Abbett and later Jennison Associates, then spent more than a decade at Fidelity Investments, one of the most respected firms in asset management, as an analyst and portfolio manager. She more recently served as Head of the Small Company Growth team and Portfolio Manager at Polen Capital before founding Pure Path Ventures, through which she coaches and advises investors, founders, and executives and serves as a fractional Chief Investment Officer. Over nearly three decades of evaluating companies across healthcare and life sciences, technology, consumer, financial services, and industrials, Rayna developed a deep understanding of what makes a business work: why some companies build durable advantage and compound over time while others falter. She has long held the conviction that the businesses that endure are those built to last, companies that invest patiently behind a long runway of growth, sustain that growth over time, and resist the short-term thinking that crowds out the right long-term decisions. She brings that long-term, owner’s perspective to the boardroom, combining the analytical rigor of a career investor with the discipline of a trained leadership coach to press on the strategy and capital allocation decisions that drive durable value and to engage management and fellow directors in honest, high-quality dialogue. Rayna currently serves as an Independent Director at Xelcis Bio, Board Chair at Raw Art Works, and Finance and Audit Committee Chair at Big Brothers Big Sisters of Eastern Massachusetts. Rayna holds a B.A. in Economics from Barnard College, Columbia University, and is a CFA® charterholder.
Mark Glickman
Board Member
Mark Glickman is the President and CEO of BioFlorida, a statewide organization dedicated to advancing Florida’s life sciences industry. In his role, Mark directs the organization’s overall strategy to enhance Florida’s competitiveness as a top global location for life sciences. Under his leadership, BioFlorida focuses on serving its members, fostering a positive business and legislative environment, advancing research commercialization, and collaborating across sectors to promote scientific progress. This includes supporting existing companies, launching startups, and attracting new businesses and talent to Florida. Mark currently sits on the Board of Directors for MetaVia (Nasdaq: MTVA) and Otsuka Precision Health, a division of Otsuka Pharmaceutical Inc. Previously, Mark served as Chief Executive Officer of TherapeuticsMD, Inc. (NASDAQ: TXMD) from 2022 until the sale of its assets to Mayne Therapeutics in January 2023. Before this, he was the Chief Business Officer, Commercial, at TherapeuticsMD, Inc., starting in June 2021. Mark also served as Chief Commercial Officer for Esperion Therapeutics, Inc. (NASDAQ: ESPR) from 2018 to December 2020, where he led the commercial division in launching the company’s first cardiovascular prescription therapy and over 1.5 billion dollars in ex-US out -license deals. From June 2015 to March 2018, Mark was the Chief Commercial Officer for Aralez Pharmaceuticals, where he built and led the commercial efforts for a previously clinical organization. Earlier in his career, Mark was Executive Vice President of Sales and Marketing at Auxilium Pharmaceuticals (Endo), where he led commercial efforts for a portfolio of thirteen pharmaceutical products. Auxilium was acquired by Endo Pharmaceuticals in 2015. His prior positions include Senior Vice President of Sales and Marketing and Vice President of Medical Devices for Otsuka America Pharmaceuticals Inc., as well as roles at Kos Pharmaceuticals (Abbott Labs) where he expanded his expertise in commercial product management.
With over 30 years of experience in the pharmaceutical and medical device industries, Mark began his career as a diagnostic sales representative and advanced to senior executive roles. He holds a Bachelor of Arts degree in Political Science from SUNY Oswego and a Master of Business Administration in Finance and International Management from NYU Stern School of Business.
Steven D. Sonenreich
Board Member
Steven D. Sonenreich, President and Chief Executive Officer, joined Mount Sinai Medical Center, Miami Beach, Florida, in 1976. After serving as Executive Vice President and Chief Operating Officer from 1990 to 1996, Mr. Sonenreich became the Chief Executive Officer of Cedars Medical Center in Miami, Florida. In November 2001, Mr. Sonenreich returned to Mount Sinai Medical Center and became its President and Chief Executive Officer. Under Mr. Sonenreich’s leadership, Mount Sinai was named as one of America’s Top Hospitals in Geriatric Medicine for five consecutive years by U.S. News and World Report, and has been nationally recognized by IBM Watson Health as a 100 Top Hospital for both 2018 and 2019.
Mr. Sonenreich spearheaded Mount Sinai’s affiliation with Columbia University, New York, New York, creating The Mount Sinai Columbia University Divisions of Cardiology, Cardiac Surgery, Urology and Orthopedics. Additionally, he oversaw a transformational expansion of the medical center, with the opening of a new freestanding emergency center in Hialeah in 2018, followed by the unveiling of a 154-bed state-of-the-art surgical tower and emergency center in 2019.
He was honored as Citizen of the Year by the Miami Beach Chamber of Commerce in 2012. He served as chair of the Florida Hospital Association Board of Trustees in 2013; and has been a member of the board of The Safety Net Hospital Alliance of Florida since 2005. Mr. Sonenreich earned his Bachelor of Arts degree from the State University of New York at Binghamton and a Master of Business Administration and Certification in Healthcare Administration from the University of Miami, Coral Gables, Florida.
MKTG-045v01